Brain Cancer - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H1 2015’, provides an overview of the Brain Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Brain Cancer Overview
- Therapeutics Development
- Pipeline Products for Brain Cancer – Overview
- Pipeline Products for Brain Cancer – Comparative Analysis
- Brain Cancer – Therapeutics under Development by Companies
- Brain Cancer – Therapeutics under Investigation by Universities/Institutes
- Brain Cancer – Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Brain Cancer – Products under Development by Companies
- Brain Cancer – Products under Investigation by Universities/Institutes
- Brain Cancer – Companies Involved in Therapeutics Development
- AbbVie Inc.
- AngioChem Inc.
- Arrien Pharmaceuticals, LLC
- BBB Therapeutics B.V.
- biOasis Technologies Inc.
- Bionomics Limited
- Bristol-Myers Squibb Company
- Cavion LLC
- Critical Outcome Technologies Inc.
- CureFAKtor Pharmaceuticals, LLC
- Diffusion Pharmaceuticals LLC
- e-Therapeutics plc
- Eisai Co., Ltd.
- Exelixis, Inc.
- GlaxoSmithKline plc
- Hutchison MediPharma Limited
- Merrimack Pharmaceuticals, Inc.
- Nanobiotix
- Nektar Therapeutics
- Nerviano Medical Sciences S.r.l.
- Neuralstem, Inc.
- Novartis AG
- Oncology Research International Limited
- Pfizer Inc.
- Philogen S.p.A.
- Phosplatin Therapeutics
- Prana Biotechnology Limited
- Puma Biotechnology, Inc.
- RadioRx, Inc.
- Sagetis Biotech, S.L.
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Stemline Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- ThromboGenics NV
- Tocagen Inc.
- Zymeworks Inc.
- Brain Cancer – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
- 2B3-101 - Drug Profile
- ANG-1005 - Drug Profile
- ANG-4043 - Drug Profile
- ARN-7016 - Drug Profile
- BNC-105 - Drug Profile
- BT-2111 - Drug Profile
- cabazitaxel - Drug Profile
- cabozantinib s-malate - Drug Profile
- CFAKC-4 - Drug Profile
- COTI-2 - Drug Profile
- dabrafenib mesylate - Drug Profile
- dacomitinib - Drug Profile
- dexanabinol - Drug Profile
- Drug for Brain Metastasis - Drug Profile
- erismodegib - Drug Profile
- etirinotecan pegol - Drug Profile
- Gene Therapy for Brain Cancer - Drug Profile
- Gene Therapy to Activate p53 for Oncology - Drug Profile
- HMPL-813 - Drug Profile
- ipilimumab - Drug Profile
- irinotecan sucrosofate liposomal - Drug Profile
- KML-001 - Drug Profile
- lapatinib ditosylate - Drug Profile
- LEQ-506 - Drug Profile
- lucanthone hydrochloride - Drug Profile
- MDNA-55 - Drug Profile
- mibefradil dihydrochloride - Drug Profile
- Monoclonal Antibody for Brain Cancer and Metastatic Breast Cancer - Drug Profile
- NBTX-IV - Drug Profile
- neratinib - Drug Profile
- nimotuzumab - Drug Profile
- NMSE-973 - Drug Profile
- NSI-566 - Drug Profile
- ORIL-007 - Drug Profile
- PB-357 - Drug Profile
- PBT-519 - Drug Profile
- pritumumab - Drug Profile
- PT-112 - Drug Profile
- RAD-1901 - Drug Profile
- radretumab - Drug Profile
- RRX-001 - Drug Profile
- SAG-002 - Drug Profile
- SAG-003 - Drug Profile
- siomycin A - Drug Profile
- SL-301 - Drug Profile
- SL-302 - Drug Profile
- Small Molecule for Brain Cancer - Drug Profile
- Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
- Small Molecule for Oncology - Drug Profile
- Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
- TB-403 - Drug Profile
- TBX-02 - Drug Profile
- TPI-287 - Drug Profile
- transcrocetinate sodium - Drug Profile
- TTL-1177 - Drug Profile
- ubidecarenone - Drug Profile
- Vaccine for Glioblastoma Multiforme - Drug Profile
- veliparib - Drug Profile
- vocimagene amiretrorepvec + flucytosine ER - Drug Profile
- Brain Cancer – Recent Pipeline Updates
- Brain Cancer – Dormant Projects
- Brain Cancer – Discontinued Products
- Brain Cancer – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Brain Cancer, H1 2015
- Number of Products under Development for Brain Cancer – Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Development by Companies, H1 2015 (Contd..1)
- Number of Products under Development by Companies, H1 2015 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Late Stage Development, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Development by Companies, H1 2015 (Contd..1)
- Products under Development by Companies, H1 2015 (Contd..2)
- Products under Development by Companies, H1 2015 (Contd..3)
- Products under Investigation by Universities/Institutes, H1 2015
- Brain Cancer – Pipeline by AbbVie Inc., H1 2015
- Brain Cancer – Pipeline by AngioChem Inc., H1 2015
- Brain Cancer – Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
- Brain Cancer – Pipeline by BBB Therapeutics B.V., H1 2015
- Brain Cancer – Pipeline by biOasis Technologies Inc., H1 2015
- Brain Cancer – Pipeline by Bionomics Limited, H1 2015
- Brain Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015
- Brain Cancer – Pipeline by Cavion LLC, H1 2015
- Brain Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015
- Brain Cancer – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
- Brain Cancer – Pipeline by Diffusion Pharmaceuticals LLC, H1 2015
- Brain Cancer – Pipeline by e-Therapeutics plc, H1 2015
- Brain Cancer – Pipeline by Eisai Co., Ltd., H1 2015
- Brain Cancer – Pipeline by Exelixis, Inc., H1 2015
- Brain Cancer – Pipeline by GlaxoSmithKline plc, H1 2015
- Brain Cancer – Pipeline by Hutchison MediPharma Limited, H1 2015
- Brain Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
- Brain Cancer – Pipeline by Nanobiotix, H1 2015
- Brain Cancer – Pipeline by Nektar Therapeutics, H1 2015
- Brain Cancer – Pipeline by Nerviano Medical Sciences S.r.l., H1 2015
- Brain Cancer – Pipeline by Neuralstem, Inc., H1 2015
- Brain Cancer – Pipeline by Novartis AG, H1 2015
- Brain Cancer – Pipeline by Oncology Research International Limited, H1 2015
- Brain Cancer – Pipeline by Pfizer Inc., H1 2015
- Brain Cancer – Pipeline by Philogen S.p.A., H1 2015
- Brain Cancer – Pipeline by Phosplatin Therapeutics, H1 2015
- Brain Cancer – Pipeline by Prana Biotechnology Limited, H1 2015
- Brain Cancer – Pipeline by Puma Biotechnology, Inc., H1 2015
- Brain Cancer – Pipeline by RadioRx, Inc., H1 2015
- Brain Cancer – Pipeline by Sagetis Biotech, S.L., H1 2015
- Brain Cancer – Pipeline by Sanofi, H1 2015
- Brain Cancer – Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
- Brain Cancer – Pipeline by Stemline Therapeutics, Inc., H1 2015
- Brain Cancer – Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
- Brain Cancer – Pipeline by ThromboGenics NV, H1 2015
- Brain Cancer – Pipeline by Tocagen Inc., H1 2015
- Brain Cancer – Pipeline by Zymeworks Inc., H1 2015
- Assessment by Monotherapy Products, H1 2015
- Assessment by Combination Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Brain Cancer Therapeutics – Recent Pipeline Updates, H1 2015
- Brain Cancer – Dormant Projects, H1 2015
- Brain Cancer – Dormant Projects (Contd..1), H1 2015
- Brain Cancer – Dormant Projects (Contd..2), H1 2015
- Brain Cancer – Dormant Projects (Contd..3), H1 2015
- Brain Cancer – Discontinued Products, H1 2015
- List of Figures
- Number of Products under Development for Brain Cancer, H1 2015
- Number of Products under Development for Brain Cancer – Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Products, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Assessment by Combination Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015
- Number of Products by Stage and Top 10 Molecule Types, H1 2015